Cell-Driven Viral Transformation
Since the advent of hybridoma technology, one of the most provocative applications for monoclonal antibodies has been immunotherapy. Early reports of experiments performed in mice suggested that monoclonal antibody therapy was beneficial against murine T-cell lymphoma (Bernstein et al., 1980) and that it might be useful to deliver potent toxins to undesirable cells in vivo [reviewed in Moller (1982)]. Murine monoclonals have more recently been administered without major adverse reactions to immunocompromised human patients with leukemia or lymphoma (Levy and Miller, 1983). Results from these studies have shown, however, that the therapeutic effects of these reagents were difficult to maintain, due in large part to a host response to mouse immunoglobulin (Ig) which resulted in accelerated clearance of successive doses (Levy and Miller, 1983). This observation together with the goal of prophylactically and therapeutically treating a broader group of human patients have provided incentive to develop human monoclonal technology.
KeywordsHuman Monoclonal Antibody Lymphoblastoid Cell Line Proliferate Cell Line Limit Dilution Analysis Spend Culture Supernatant
Unable to display preview. Download preview PDF.
- Andriole, V. T., 1978, Pseudomonas bacteremia: Can antibiotic therapy improve survival, J. Lab. Clin. Med. 94: 196–200.Google Scholar
- Boyum, A., 1968, Isolation of mononuclear cells and granulocytes from human blood, Scand. J. Clin. Lab. Invest. 21 (Suppl. 97): 77–89.Google Scholar
- Brokopp, C. D., and Farmer, J. J., III, 1979, Typing methods for Pseudomonas aeruginosa, in: Pseudomonas aeruginosa: Clinical Manifestations of Infection and Current Therapy ( R. G. Doggett, ed.), Academic Press, New York, Chapter 5.Google Scholar
- Ernberg, I., and Klein G., 1979, EB virus-induced antigens, in: The Epstein-Barr Virus ( M. A. Epstein and B. G. Achong, eds.), Springer, New York, Chapter 3.Google Scholar
- Larrick, J. W., and Buck, D. W., 1984, Practical aspects of human monoclonal antibody production, Bio Techniques 2: 6–14.Google Scholar
- Moller, G. (ed.), 1982, Antibody Carriers of Drugs and Toxins in Tumor Therapy, Immunological Reviews, Volume 62, Munksgaard, Copenhagen.Google Scholar
- Pollack, M., 1979, Antibody-mediated immunity in Pseudomonas disease and its clinical application, in: Immunoglobulins: Characteristics and Uses of Intravenous Preparations ( B. M. Alving and J. S. Finlayson, eds.), U.S. Department of Health and Human Services, Washington, D.C., pp. 73–79.Google Scholar
- Tam, M. R., Buchanan, T. M., Sandstrom, E. G., Holmes, K. K., Knapp, J. S., Siadak, A. W., and Nowinski, R. C., 1982, Serological classification of Neisseria gonorrhoeae with monoclonal antibodies, Infect. Immunol. 36: 1042–1053.Google Scholar
- Van Furth, R., and van Zwet, T. L., 1973, In vitro determination of phagocytosis and intracellular killing by polymorphonuclear and mononuclear phagocytes, in: Handbook of Experimental Immunology, Volume 2, 2nd ed. ( D. M. Weir, ed.), Blackwell, Oxford, Chapter 36.Google Scholar
- Westphal, O., Luderitz, O., and Bister, F., 1952, Über die Extraktion von Bakterien mit Phenol/Wasser, Z. Naturforsch. 79: 148–155.Google Scholar
- Westphal, O., Jann, K., and Himmelspach, K., 1983, Chemistry and immunochemistry of bacte- rial lipopolysaccharides as cell wall antigens and endotoxins, Progr. Allergy 33: 9–39.Google Scholar
- Winger, L., Winger, C., Shastry, P., Russell, A., and Longenecker, M., 1983, Efficient generation in vitro, from human peripheral blood cells, of monoclonal Epstein—Barr virus transformants producing specificity antibody to a variety of antigens without prior deliberate immunization, Proc. Natl. Acad. Sci. USA 80: 4484–4488.PubMedCrossRefGoogle Scholar